NEW YORK (GenomeWeb) – Diagnostics firm Biodesix said today that it is collaborating with Swiss proteomics firm Biognosys on protein biomarker identification and development.
The collaboration is focused on using Biognosys' HRM mass spec technology to facilitate Biodesix's companion diagnostic work.
Biodesix said that it plans to use the HRM approach to enable reproducible quantitation of thousands of proteins across patient samples, helping it identify clinically useful biomarkers as part of its companion diagnostic program.
A form of data-independent acquisition mass spectrometry, HRM is advertised by Biognosys as providing more accurate and reproducible protein quantitation than conventional shotgun-style mass spec analysis.
"By combining our proven and comprehensive protein quantification technology with Biodesix's understanding of the clinical research and diagnostics market, we can identify more clinically relevant classifiers and biomarkers," Biognosys CEO Oliver Rinner said in a statement.